Envista Holdings Co. (NYSE:NVST) Shares Sold by Sepio Capital LP

Sepio Capital LP decreased its holdings in Envista Holdings Co. (NYSE:NVST) by 23.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,800 shares of the company’s stock after selling 11,619 shares during the period. Sepio Capital LP’s holdings in Envista were worth $748,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Amalgamated Bank raised its holdings in Envista by 0.7% in the fourth quarter. Amalgamated Bank now owns 80,380 shares of the company’s stock valued at $1,551,000 after acquiring an additional 523 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock valued at $44,000 after purchasing an additional 538 shares in the last quarter. M&T Bank Corp lifted its position in shares of Envista by 4.2% during the 4th quarter. M&T Bank Corp now owns 16,621 shares of the company’s stock worth $320,000 after purchasing an additional 676 shares during the last quarter. Assetmark Inc. grew its stake in shares of Envista by 2.5% during the fourth quarter. Assetmark Inc. now owns 39,624 shares of the company’s stock worth $764,000 after purchasing an additional 983 shares in the last quarter. Finally, Xponance Inc. increased its holdings in Envista by 5.8% in the fourth quarter. Xponance Inc. now owns 19,726 shares of the company’s stock valued at $381,000 after buying an additional 1,077 shares during the last quarter.

Envista Price Performance

Envista stock opened at $15.47 on Monday. The business has a fifty day moving average of $19.18 and a two-hundred day moving average of $19.53. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The company has a market cap of $2.66 billion, a P/E ratio of -2.38, a price-to-earnings-growth ratio of 1.27 and a beta of 1.12. Envista Holdings Co. has a one year low of $14.77 and a one year high of $23.00.

Envista (NYSE:NVST) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. As a group, analysts predict that Envista Holdings Co. will post 1 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Piper Sandler lifted their price target on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a report on Thursday, March 6th. Jefferies Financial Group increased their price target on shares of Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research note on Thursday, January 23rd. New Street Research set a $19.00 price objective on shares of Envista in a research report on Thursday, March 6th. Finally, Morgan Stanley dropped their target price on shares of Envista from $20.00 to $19.00 and set an “equal weight” rating on the stock in a research report on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, Envista currently has a consensus rating of “Hold” and an average target price of $20.18.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.